Evatanepag

DB12022InvestigationalSmall molecule

Evatanepag has been used in trials studying the treatment of Tibial Fractures.

Mechanism: Pharmacologically active on Prostaglandin E2 receptor EP2 subtype
Curator reviewed
Formula / weight: C₂₅H₂₈N₂O₅S · 468.57 g/mol (avg)
Code names: Cp-533,536

Resolves to

Compound

Structure

InChIKeyWOHRHWDYFNWPNG-UHFFFAOYSA-NSMILESCC(C)(C)C1=CC=C(CN(CC2=CC=CC(OCC(O)=O)=C2)S(=O)(=O)C2=CC=CN=C2)C=C1

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Evatanepag, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.